ArticleFrontiers in pharmacology2022
Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Evaluating the efficacy and safety of antibody-drug conjugates in non-small cell lung cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses.BMC cancer · 2025Pooled it
- Infectious Complications of Antibody-Drug Conjugates: A Review of Safety Data from FDA-Approved Agents.Current oncology reports · 2026Review
- Comprehensive Sepsis Risk Prediction in Leukemia Using a Random Forest Model and Restricted Cubic Spline Analysis.Journal of inflammation research · 2025Article
- Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database.Frontiers in pharmacology · 2025Article
- Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.Targeted oncology · 2024Article
- Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study.Frontiers in pharmacology · 2024Article
- A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS).Frontiers in pharmacology · 2024Article
- Causal relationships between lung cancer and sepsis: a genetic correlation and multivariate mendelian randomization analysis.Frontiers in genetics · 2024Article
- Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.Scientific reports · 2023Article
- Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.